🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Why Kezar Life Sciences Shares Are Getting Hammered

Published 04/05/2022, 15:59
Updated 04/05/2022, 16:41
© Reuters.  Why Kezar Life Sciences Shares Are Getting Hammered
KZR
-

Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib.

Kezar Life Sciences says most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed.

Kezar Life Sciences added that Zetomipzomib demonstrates a favorable safety and tolerability profile, including in the PRESIDIO Open-label Extension Study where weekly zetomipzomib has been administered for up to an additional 77 weeks.

See Also: Why Lyft (NASDAQ:LYFT) Shares Are Slamming The Brakes Today

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

According to data from Benzinga Pro, Kezar Life Sciences has a 52-week high of $18.55 and a 52-week low of $4.61.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.